Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 8/20 | 0.83 |
| ▸ | P2RY2 | P41231 | 12/20 | 0.81 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.81 |
| ▸ | P2RY14 | Q15391 | 7/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30679287 | 1.00 | P2RY6 (0.83) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL4166158 | 1.00 | P2RY6 (0.83) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL2683846 | 1.00 | P2RY6 (0.83) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL157645 | 1.00 | P2RY6 (0.83) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL4071893 | 1.00 | P2RY6 (0.83) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL157644 | 1.00 | P2RY6 (0.83) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL2056922 | 1.00 | P2RY6 (0.83) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL2056709 | 1.00 | P2RY6 (0.83) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL2056916 | 1.00 | P2RY6 (0.83) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL317204 | 1.00 | P2RY6 (0.83) | P2RY6P2RY2P2RY4P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 615 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | claimed |
| EP-4213828-B1 | PHARMACEUTICAL COMPOSITION COMPRISING URIDINE AND PYRUVATE FOR REGULATING THE PROLIFERATION, ACTIVITY AND SURVIVAL OF IMMUNE CELLS | GV SQUARED S R L (IT) | 2025-08-27 | — | — | EP | claimed |
| WO-2024229600-A1 | SOLUBLE BIOMOLECULAR GLASS AND USE THEREOF | 中国科学院过程工程研究所 | 2024-11-14 | — | — | WO | claimed |
| CN-116773710-A | Kit for covering metabolome and metabolic flow of multiple metabolites and use method | 清华大学 | 2023-09-19 | — | — | CN | claimed |
| US-11739357-B2 | Recombinant microorganism for producing citicoline and method for producing citicoline | SUZHOU BIOSYNTHETICA CO., LTD (CN) | 2023-08-29 | — | — | US | claimed |
| EP-4213828-A1 | PHARMACEUTICAL COMPOSITION COMPRISING URIDINE AND PYRUVATE FOR REGULATING THE PROLIFERATION, ACTIVITY AND SURVIVAL OF IMMUNE CELLS | GV Squared S.r.l. (IT) | 2023-07-26 | — | — | EP | claimed |
| EP-3650534-B1 | RECOMBINANT MICROORGANISM FOR PRODUCING CYTIDINE DIPHOSPHATE AND METHOD FOR PRODUCING CYTIDINE DIPHOSPHATE | SUZHOU BIOSYNTHETICA CO LTD (CN) | 2023-03-15 | — | — | EP | claimed |
| WO-2022144799-A1 | IMMUNOSTIMULATING FOOD SUPPLEMENT AND USE THEREOF | PHARSMART S.R.L. (IT) | 2022-07-07 | — | — | WO | claimed |
| EP-3989992-A2 | THERAPEUTIC COMPOSITIONS AND METHODS OF USING SEROTONIN MODULATING MICROBIOME-BASED INTERVENTIONS TO TREAT SEROTONIN-RELATED DISEASES OR DISORDERS | Holobiome, Inc. (US) | 2022-05-04 | — | — | EP | claimed |
| WO-2022058271-A1 | PHARMACEUTICAL COMPOSITION COMPRISING URIDINE AND PYRUVATE FOR REGULATING THE PROLIFERATION, ACTIVITY AND SURVIVAL OF IMMUNE CELLS | GV SQUARED S.R.L. (IT) | 2022-03-24 | — | — | WO | claimed |
| WO-2003075684-A1 | SEASONING COMPOSITIONS | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2003-09-18 | — | — | WO | claimed |
| EP-1344459-A1 | Seasoning compositions | Société des Produits Nestlé S.A. (CH) | 2003-09-17 | — | — | EP | claimed |
| US-20030162164-A1 | Comparative phenotype analysis of cells, including testing of biologically active compounds | BIOLOG, INC. | 2003-08-28 | — | — | US | claimed |
| US-20020058244-A1 | Method for detecting uracil biosynthesis inhibitors and their use as herbicides | BASF AKTIENGESELLSCHAFT (DE) | 2002-05-16 | — | — | US | claimed |
| US-20020025560-A1 | Processes for producing sugar nucleotides and complex carbohydrates | KYOWA HAKKO BIO CO., LTD. (JP) | 2002-02-28 | — | — | US | claimed |
| US-6344344-B1 | A BACTERIUM THAT IS REISTANT TO GROWTH INHIBITION BY A PYRIMIDINE ANALOGUE; FOR URIDINE-5'-MONOPHOSPHATE PRODUCTION IN CULTURE MEDIUM | AJINOMOTO CO., INC. (JP) | 2002-02-05 | — | — | US | claimed |
| EP-1096023-A2 | Method for producing uridine-5'- monophosphate by fermentation using mutant strains of coryneform bacteria | Ajinomoto Co., Inc. (JP) | 2001-05-02 | — | — | EP | claimed |
| EP-0870841-A1 | PROCESSES FOR PRODUCING SUGAR NUCLEOTIDES AND COMPLEX CARBOHYDRATES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1998-10-14 | — | — | EP | claimed |
| EP-0343772-A2 | Process for preparing platinum green complex | AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 1989-11-29 | — | — | EP | claimed |
| US-4577012-A | ABSORPTION ON ACTIVATED CARBON, ELUTION WITH ALKALI HYDROXIDE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1986-03-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058244-A1 | Method for detecting uracil biosynthesis inhibitors and their use as herbicides | UMPS, UGP2, UNG | P2RY6 939/4885P2RY2 1272/4885P2RY4 1059/4885 |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | P2RY6 1432/4885P2RY2 3116/4885P2RY4 3356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.